FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136552706> ?p ?o ?g. }

• W3136552706 endingPage "267" @default.
• W3136552706 startingPage "259" @default.
• W3136552706 abstract "Fosravuconazole L-lysine ethanolate (F-RVCZ), a ravuconazole prodrug, is a newly available agent with high expectations for efficacy in the treatment of onychomycosis. However, clinical data regarding the efficacy of F-RVCZ are limited because the drug was launched only in Japan in 2018. Therefore, we analyzed the outcome of F-RVCZ therapy in the treatment of onychomycosis at outpatient dermatology clinics in Japan. We examined data for 109 patients (68 male, 41 female) with varying clinical type, including total dystrophic onychomycosis and dermatophytoma, and a wide range of age groups, including the elderly. The complete cure rate at 12 weeks was 6.4% (7/109) and 67.9% (74/109) at the last visit (mean time to last visit: 32 ± 14.2 weeks). Mean rate of improvement in the affected nail area was 49.1 ± 23.3% at 12 weeks and 86.8 ± 22.4% at the last visit. Efficacy at 12 weeks and the last visit, respectively, was as follows: none, 4 cases and 1 case; slight, 35 cases and 4 cases; moderate, 51 cases and 21 cases; significant, 12 cases and 9 cases; complete cure, 7 cases and 74 cases. There were no serious adverse events. This retrospective survey was the first large-scale analysis of actual clinical practice outcomes and had minimal exclusions. Compared to previous reports, our results demonstrated excellent efficacy of F-RVCZ therapy in a variety of patients. Considering our results and the ease of oral administration (1 capsule/day for 12 weeks) and few adverse events, F-RVCZ therapy appears to be a useful option for the treatment of onychomycosis." @default.
• W3136552706 created "2021-03-29" @default.
• W3136552706 creator A5027440523 @default.
• W3136552706 creator A5057860815 @default.
• W3136552706 creator A5074448264 @default.
• W3136552706 creator A5085530179 @default.
• W3136552706 date "2021-03-22" @default.
• W3136552706 modified "2023-10-16" @default.
• W3136552706 title "Treatment Outcome with Fosravuconazole for Onychomycosis" @default.
• W3136552706 cites W1502209728 @default.
• W3136552706 cites W1982740731 @default.
• W3136552706 cites W1986000961 @default.
• W3136552706 cites W1988645607 @default.
• W3136552706 cites W2050582008 @default.
• W3136552706 cites W2052595254 @default.
• W3136552706 cites W2073148029 @default.
• W3136552706 cites W2134790121 @default.
• W3136552706 cites W2148472037 @default.
• W3136552706 cites W2161267677 @default.
• W3136552706 cites W2559245084 @default.
• W3136552706 cites W2600282867 @default.
• W3136552706 cites W2606614846 @default.
• W3136552706 cites W2637073256 @default.
• W3136552706 cites W2888933585 @default.
• W3136552706 cites W2952911388 @default.
• W3136552706 cites W2964040977 @default.
• W3136552706 cites W2965104014 @default.
• W3136552706 cites W2970837117 @default.
• W3136552706 cites W2990986518 @default.
• W3136552706 cites W3023750229 @default.
• W3136552706 cites W3088001461 @default.
• W3136552706 cites W3093918926 @default.
• W3136552706 cites W4233745095 @default.
• W3136552706 cites W4385267660 @default.
• W3136552706 cites W2308822269 @default.
• W3136552706 doi "https://doi.org/10.1007/s11046-021-00540-6" @default.
• W3136552706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33754205" @default.
• W3136552706 hasPublicationYear "2021" @default.
• W3136552706 type Work @default.
• W3136552706 sameAs 3136552706 @default.
• W3136552706 citedByCount "7" @default.
• W3136552706 countsByYear W31365527062022 @default.
• W3136552706 countsByYear W31365527062023 @default.
• W3136552706 crossrefType "journal-article" @default.
• W3136552706 hasAuthorship W3136552706A5027440523 @default.
• W3136552706 hasAuthorship W3136552706A5057860815 @default.
• W3136552706 hasAuthorship W3136552706A5074448264 @default.
• W3136552706 hasAuthorship W3136552706A5085530179 @default.
• W3136552706 hasBestOaLocation W31365527062 @default.
• W3136552706 hasConcept C126322002 @default.
• W3136552706 hasConcept C141071460 @default.
• W3136552706 hasConcept C16005928 @default.
• W3136552706 hasConcept C167135981 @default.
• W3136552706 hasConcept C197934379 @default.
• W3136552706 hasConcept C2777071850 @default.
• W3136552706 hasConcept C2778236110 @default.
• W3136552706 hasConcept C2779548794 @default.
• W3136552706 hasConcept C2992053201 @default.
• W3136552706 hasConcept C71924100 @default.
• W3136552706 hasConceptScore W3136552706C126322002 @default.
• W3136552706 hasConceptScore W3136552706C141071460 @default.
• W3136552706 hasConceptScore W3136552706C16005928 @default.
• W3136552706 hasConceptScore W3136552706C167135981 @default.
• W3136552706 hasConceptScore W3136552706C197934379 @default.
• W3136552706 hasConceptScore W3136552706C2777071850 @default.
• W3136552706 hasConceptScore W3136552706C2778236110 @default.
• W3136552706 hasConceptScore W3136552706C2779548794 @default.
• W3136552706 hasConceptScore W3136552706C2992053201 @default.
• W3136552706 hasConceptScore W3136552706C71924100 @default.
• W3136552706 hasIssue "2" @default.
• W3136552706 hasLocation W31365527061 @default.
• W3136552706 hasLocation W31365527062 @default.
• W3136552706 hasOpenAccess W3136552706 @default.
• W3136552706 hasPrimaryLocation W31365527061 @default.
• W3136552706 hasRelatedWork W111998303 @default.
• W3136552706 hasRelatedWork W1999072654 @default.
• W3136552706 hasRelatedWork W2003293898 @default.
• W3136552706 hasRelatedWork W2048735574 @default.
• W3136552706 hasRelatedWork W2115184474 @default.
• W3136552706 hasRelatedWork W2176475586 @default.
• W3136552706 hasRelatedWork W2316244737 @default.
• W3136552706 hasRelatedWork W2356342213 @default.
• W3136552706 hasRelatedWork W3084498133 @default.
• W3136552706 hasRelatedWork W1581470256 @default.
• W3136552706 hasVolume "186" @default.
• W3136552706 isParatext "false" @default.
• W3136552706 isRetracted "false" @default.
• W3136552706 magId "3136552706" @default.
• W3136552706 workType "article" @default.